Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

Core Viewpoint - Soleno Therapeutics, Inc. is facing a class action lawsuit due to alleged concealment of significant safety risks related to its lead drug, DCCR, which has negatively impacted its stock performance and investor confidence [1][4]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Soleno securities between March 6, 2025, and November 4, 2025, with a deadline of May 5, 2026, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Stock Performance and Market Reaction - Soleno's stock price fell approximately 27% on November 4, 2025, following the release of its third-quarter financial results, which revealed a disruption in the commercial launch of DCCR [3]. - Prior to this, there was a 19% drop in share value over two trading days starting September 10, 2025, after a patient death was reported post-DCCR administration [3]. Group 3: Allegations of Concealment - The lawsuit alleges that Soleno concealed significant safety evidence in its Phase 3 clinical trial, particularly downplaying risks associated with "excess fluid retention," leading to a 12% stock decline in August 2025 [4]. - The undisclosed safety risks are claimed to have undermined DCCR's commercial viability, resulting in prescriber reluctance and challenges in patient adoption [4].